Amaç: Meme kanseri insidensi yaşla birlikte artar ve hastaların yaklaşık %85'i 50 yaşından sonra tanı alır. Genç hastalarda meme kanserinin klinik seyri ileri yaştaki hastalara göre daha kötüdür. Çalışmamızın amacı çok erken yaş meme kanserli hastalar ile ileri yaş meme kanserli hastalar arasında Bcl-2 ekspresyonu ve Ki-67 proliferasyon indeksi açısından fark olup olmadığının belirlenmesi ve eğer belirlenebilirse bu farkın klinik öneminin araştırılması- 
Introduction
Breast cancer is the neoplasia with the highest incidence in the female population worldwide. Incidence of breast cancer increases with age and nearly 85% of them are diagnosed after the age of 50 [1] . Very young patients (≤35 years) with breast cancer constitute 2.7% of all patients in western countries [2] . This ratio is between 10-25 % in Asian countries whereas it is established as 17% in our country [3;4] . Clinical outcome of breast cancer in young patients is worse than older patients. Histologic grade and lymph node involvement rate are found to be high and a lower hormone receptor expression is found in these patients at the time of diagnosis [5] . Genetic inheritance and BRCA1, BRCA2 mutations are observed with a higher rate in young patients [6] . Bcl-2 gene is firstly identified in patients with B cell follicular lymphoma establishing t(14;18) translocation but its expression is not related to this translocation. Bcl-2 increases the life cycle of the cell by inhibiting apopitosis and therefore causes the cell to come accross mutagenic factors more. In most of the human tumours a relation between bcl-2 expression and survival has been shown [7] . In patients with breast cancer, variable expression rates of Bcl-2 have been determined [8] . Besides, response to adjuvant endocrine therapy is found to be better in patients with bcl-2 expression [9;10] . Ki-67 is a marker that is widely used to determine the proliferating cells . Results of the studies that searched the relationship between Ki-67 expression and prognosis in patients with breast cancer are not clear. While Ki-67 proliferation index was found in association with bad prognosis in the majority of the studies, this association was not shown in other studies [11] [12] [13] . The aim of our study is to search the difference in expression of bcl-2 and Ki-67 between young and older women with breast cancer, and if there is any; its clinical importance.
Material and Method
Choosing the patients This study includes the 15 female patients under the age of 35 years, who were histopathologically diagnosed with invasive breast carcinoma, and followed up at the Medical Oncology Clinic of Education and Research Hospital between 2008 and 2010. Thirty patients with the same diagnosis who were over the age of 35 years were chosen as the control group. Patients whose screening and clinical staging studies were completed were staged according to the 7th Staging System of the American Joint Committee on Cancer (AJCC). Patients' files were analysed and information on age, gender, disease stage and other clinicopathological characteristics were obtained. Patients without histopathological diagnosis and patients whose initial treatments were started at another center and continued at our center were excluded from the study.
Immunohistochemistry
Tumor samples obtained right after the surgery were fixed in 10% formaldehyde. After fixation, tumor samples were embeded in paraffin. Then, histologic sections with a 4 µm thickness were obtained from paraffin blocks and were initially stained with hemotoxylin-eosine for assessment. The histologic sections were de-paraffinized in incubators at 60°C for one hour. Afterwards, they were kept in xylene for 10 minutes and in 100% alcohol for 5 minutes and then washed in water. Slides were kept in solution buffered with 10% citrate solution in microwave at maximum power (800 watts) for 15 minutes. Then the power was decreased to the half and they were kept in the microwave for another 20 minutes. Slides taken out of the microwave were kept in room temperature for 20 minutes. Endogenous peroxidase activity was removed by being kept in 3% hydrogen peroxide for 20 minutes. Slides washed in distilled water were treated with 3x5 PBS and protein blockage was dripped on them. Five minutes later, Ki-67 and Bcl-2 antibodies were dripped on the slides without washing off the blockage. After being kept in primer antibody for 30 minutes, they were taken into PBS and washed for 5 minutes. Afterwards, they were treated with biotinylated secondary antibody for 20 minutes and washed in PBS for 5 minutes. They were kept with peroxidase conjugate antibody for 20 minutes. Then they were washed in PBS for 5 minutes. They were kept in chromogenous (DAB) for 5 minutes. Slides washed under tap water were adversely stained with haematoxylene. They were dehydrated, dried and mounted with entellane. For the staining of the samples Ki-67 protein, lyophilized monoclonal mouse antibody (clone B P53;12, 1:100, Invitrogen, Carmennillo, Canada) and Bcl-2 onco-protein, lyophilized mouse monoclonal antibody (clone100/D5, 1:50, Thermo Scientific, Fremont, USA) were used. After the staining, slides were inspected under Nicon Eclipse 80 microscope.
Immunohistochemistry scoring
Slides were evaluated by two pathologists (ASA, DS) who did not know the clinical features of the patients. Each section that was stained by immunohistochemical method was examined under optical microscope. Bcl-2 expressions were assessed according to the cytoplasmic staining of the cells. Interval value for Bcl-2 staining was accepted as 10%. If Bcl-2 staining was more than 10%, it was considered as positive expression, 10% or less staining was accepted as negative expression [7] . The areas with the highest nuclear staining were selected for Ki-67 and 1000 tumor cells were counted. The ratio of tumor cells were calculated and their staining indices were identified as percentage. The interval value for Ki-67 was determined as 10%, and a staining index ≥ 10% was accepted as high, 1% to 10% staining was accepted as low, no staining was accepted as nil [14] .
Statistical Analysis
Statistical analyses were performed using the SPSS software version 15. Differences between groups were inspected by using Chi-square and Man Whitney U tests. A p value of <0.05 was considered significant.
Results
A total of 45 patients; 15 (33.3%) of whom were under the age of 35 years (Group A) and 30 (71.7%) of whom were over the age of 35 years (Group B) were enrolled in this study. Median age was 32.4 (range 25-35 years) in Group A and 52.6 (range 38-71 years) in Group B patients. Thirteen of the Group A patients had a diagnosis of invasive ductal carcinoma whereas 2 of them had a diagnosis of invasive lobular carcinoma and all of the Group B patients had a diagnosis of invasive ductal carcinoma. Expression of estrogen receptor (ER) and progesterone receptor (PR) showed no difference between Group A and B patients (p:0.612, p:0.642). There were also no difference in expression of Her2 between the two groups (p:0.245). In Group A patients a more advanced stage disease was observed. (Table 1) Bcl-2 expression was found positive in 33 (73.3%) and negative in 12 (26.7%) patients. There were no difference in expression of bcl-2 between Group A and Group B patients (p:0.475). No significant relationship was found between Bcl-2 expression and T stage, lymph node status (p:0.849, p:0.746). A meaningful relationship was observed between expression of bcl-2 and hormon receptors , being more significant in ER (p:0.001,p<0.001). ER expression was found as 90.9% in in Bcl-2 positive group and 40.7% in Bcl-2 negative group. Her-2 expression was not different in Bcl-2 positive and negative groups (p:0.06). Ki-67 proliferation index was found negative in 8 patients (17.8%), low in 10 patients (22.2%) and high in 27 patients (60%). The relationship of Ki-67 proliferation index between Group A and Group B patients was analysed by Man Whitney U test and no relation was found between the two groups (p:0.555). There were no meaningful relationship between Ki-67 proliferation index and Bcl-2 expression (p:0.736).
Discussion
Breast cancer is a heterogoneous disease in terms of clinical and pathological features and response to therapy. Conventional histologic classification of breast cancer does not suggest adequate information about the clinical outcome. Histologic type, grade and size of the tumour, expression of ER, PR and HER2 receptors, leymph node and metastasis status are considered as the important prognostic factors. Age of the patient is also considered as another prognostic factor. Age is related to prognosis independent of the performance score of the patient [15;16] . Breast cancer in very young premenopousal patients behave more agressively than postmenopousal patients with an older age. As in our study, many other studies established that these yuong patients have a disease of advanced stage at the time of diagnosis [17;21] . DNA microarray studies established that different molecular subtypes in breast cancer are related with different clinical outcome [22] . In our study, the role of the apopitotic marker Bcl-2 and the cell proliferative marker Ki67 in clinical progress between very young patients (Group A) and others (Group B) was searcehed and no difference was observed between the two groups. Although we found no difference in expression of ER, PR and HER2 between Group A and Group B patients, some studies suggest that there is a difference in expression of these receptors between the two groups. In their large series Colleoni et al.. [23] found that ER and PR negativity were significant in patients with the age of 35 years when compared to patients over the age of 35. Also, rate of Ki-67 expression was found higher in these patients. Expression of HER2 was not found different. In their study, similiar to our study, the incidence of grade 3 tumours was found higher in young patients. Bcl-2 expression had been searched in many types of cancer and in many of the studies it had been shown as a good prognostic factor. Varaible expression of Bcl-2 in normal duct epithelium, intraductal carcinoma and invasive ductal carcinoma was established in different studies. In breast tissue, Bcl-2 expression was found as 96% in normal duct epithelium, 79% in intraductal carcinoma and 45% in invasive carcinoma. It was also shown that Bcl-2 expression has decreased in the development of carcinoma from the normal duct epithelium [24] . It was determined that Bcl-2 expression is related to well differantiation and ER expression, in breast cancer [25] . There are studies establishing the prognostic importance of Bcl-2 expression whereas some studies show vice-versa [26] . Yu et al. [27] published a study in which they evaluated 40 patients under the age of 35 and 40 postmenopousal patients over the age of 60 and found Bcl-2 expression as 19/40 in the group of young patients and as 30/40 in the group of older patients and showed a significant difference between the two groups. In their study, different from our study; e negative correlation was found between Bcl-2 expression and histologic grade and lymph node metastasis. A positive correlation was established between Bcl-2 expression and ER, PR expression, similiar to our study. In similiar studies concerning ductal carcinoma in situ (DCIS) cases, contrary to invasive ductal carcinoma, no differnce was determined between age groups and Bcl-2 expression [28] . Although many studies establish that Ki-67 proliferation index is higher in very young patients, we were not able to determine a similiar result in our study [29] . We think that this is due to the low number of patients under the age of 35 years , in our study. In a study in which Bcl-2 expression in breast cancer was searched, Bcl-2 expression was found as 4.1% and ve Bcl-2 expression was found in correlation with a lower Ki-67 proliferation index. Besides, Bcl-2 expression was found in a lower rate in premenopousal patients , in the same study [30] .
There is a few number of studies in which Bcl-2 expression and Ki-67 proliferation index have been evaluated together in very young patients with breast cancer. Choi et al. [34] searched 103 patients between 25-45 years old with breast cancer and found Bcl-2 expression as 35.6% and Ki-67 proliferation index as 39.7% in their study.
In conclusion, the bad progress in very young patients suggest that this subtype of breast cancer acquires a different tumour biology. Therefore, we think that it is important to demonstrate prognostic factors spesific to this group in order to plan proper treatment fort this group.
